Compare AAOI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | IBRX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2013 | N/A |
| Metric | AAOI | IBRX |
|---|---|---|
| Price | $38.11 | $2.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $33.60 | $9.71 |
| AVG Volume (30 Days) | 5.5M | ★ 13.5M |
| Earning Date | 02-25-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $421,712,000.00 | $82,555,000.00 |
| Revenue This Year | $85.86 | $667.18 |
| Revenue Next Year | $64.48 | $93.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 101.25 | ★ 1025.95 |
| 52 Week Low | $9.71 | $1.83 |
| 52 Week High | $41.96 | $4.27 |
| Indicator | AAOI | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 52.47 |
| Support Level | $34.02 | $1.95 |
| Resistance Level | $41.35 | $2.29 |
| Average True Range (ATR) | 3.62 | 0.10 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 76.25 | 69.12 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.